ALGS
Aligos Therapeutics, Inc.11.47
-0.53-4.42%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
70.58MP/E (TTM)
-Basic EPS (TTM)
-13.54Dividend Yield
0%Recent Filings
8-K
Aligos Q3 loss widens on R&D
Aligos Therapeutics reported Q3 2025 net loss of $31.5 million, up from $19.3 million last year, driven by $23.9 million in R&D expenses for the pevifoscorvir sodium Phase 2 trial, now enrolling in multiple countries. Cash reserves hit $99.1 million, funding operations into Q3 2026. Pipeline advances include Phase 1 data presentations at The Liver Meeting and preclinical synergy for ALG-055009 in obesity combos. Yet risks loom in drug development timelines.
10-Q
Q3 FY2025 results
Aligos Therapeutics posted a Q3 net loss of $31.5M, up from $19.3M a year earlier, driven by $23.9M in R&D spend versus $16.8M last year, while revenue from customers dipped to $0.7M from $1.3M. Operating loss widened to $28.4M from $20.1M, but a $4.2M hit from the 2023 warrants fair value change dragged net results lower—yet YTD through September, the company swung to a slim $4.3M net loss from $49.1M last year, thanks to a $59.0M warrants gain. Cash swelled to $99.1M after a February 2025 PIPE netting $101.4M, funding ops into Q3 2026. No non-GAAP metrics disclosed in the 10-Q. Clinical trial delays from enrollment hurdles or regulatory snags remain a key risk.
10-Q
Q2 FY2025 results
Aligos Therapeutics narrowed its Q2 operating loss to $18.6M from $26.4M y/y, driven by R&D cuts to $14.0M from $21.1M as the biotech trims HBV and MASH programs. Revenue from customers dipped to $1.0M from $1.1M, yet a $1.7M gain on 2023 warrant fair value swung net loss to $15.9M versus $5.1M income last year; YTD, net income hit $27.2M on $63.2M warrant gains, reversing $29.8M loss (derived). Cash swelled to $122.9M after February's $101M PIPE, funding ops into 2026. No non-GAAP metrics disclosed in the 10-Q. Competition from established antivirals pressures HBV progress.
8-K
Aligos Q2 loss, pipeline advances
Aligos Therapeutics reported Q2 2025 net loss of $15.9 million, or $(1.53) per share, versus $5.1 million net income last year, while cash reserves swelled to $122.9 million from $56.9 million, funding operations into H2 2026. Phase 2 B-SUPREME trial for HBV candidate ALG-000184 advances with dosing imminent after regulatory nods in multiple countries; Phase 1 data showed 60% of HBeAg+ subjects achieving deep viral suppression at week 48. ALG-055009's MASH trial hit liver fat reduction endpoints, yet partnership talks continue amid funding needs.
8-K
Aligos expands shares, plan reserves
Aligos Therapeutics boosted its authorized voting common stock to 100 million shares and non-voting to 15.8 million, effective June 25, 2025, while approving a 1 million share increase to its 2020 Incentive Award Plan reserves. These moves, passed at the annual meeting, enhance flexibility for equity incentives amid biotech talent competition. Directors K. Peter Hirth, Heather Preston, and Margarita Chavez were reelected. Yet, dilution risks loom for shareholders.
ABUS
Arbutus Biopharma Corporation
4.59-0.36
AGNPF
Algernon Pharmaceuticals Inc.
0.06-0.00
AIM
AIM ImmunoTech Inc.
1.38+0.06
ALT
Altimmune, Inc.
5.03-0.25
ASMB
Assembly Biosciences, Inc.
33.50-1.10
ENTA
Enanta Pharmaceuticals, Inc.
14.85-0.02
KROS
Keros Therapeutics, Inc.
21.53+0.30
SGMT
Sagimet Biosciences Inc. - Seri
6.05+0.02
VIR
Vir Biotechnology, Inc.
6.48-0.24
VIRX
Viracta Therapeutics, Inc.
0.01+0.00